Bangalore, Mar 17, 2010: GVK Biosciences, one of the Asia's leading contract research organizations, has commissioned its new clinical pharmacology unit (CPU) in Ahmedabad, India. The Ahmedabad CPU adds 110 beds to GVK BIO's existing capacity of 144 beds. The new CPU will conduct a variety of studies in healthy volunteers.

Ahmedabad was the most preferred and logical destination for expansion considering the volunteer pool accessibility and proximity to about 10 CROs and leading pharma companies. With three clinical wards and 110 beds, the unit is the state-of-the-art and designed to suit all regulatory requirements. It also has special housing facilities for female volunteers. Key features of this unit include access to special population like young women, post-menopausal women, diseased population and access to about 12,000 healthy volunteers.

"The opening of the new GVK BIO CPU reflects our commitment to offer faster recruitment solutions to our customers. The facility has been audited by the DCGI and we have initiated our first study at the Ahmedabad facility," said Manni Kantipudi, President, GVK Biosciences.

GVK BIO's CPU is a top service provider of bioequivalence studies to generic pharma companies globally. The CPU unit, operational from 2004 in Hyderabad, has undergone several international audits, inspections and has key accreditations to its credit including the US FDA, DCG(I), ANVISA (Brazil), AFSSAPS (France), WHO and the Ministry of Health, Turkey. In addition to the healthy volunteer population, the Ahmedabad facility gives access to diseased population in psychiatry, metabolism, cardiovascular and neurology.